EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

Marie-Eve Beaulieu, Sandra Martínez-Martín, Jastrinjan Kaur, Virginia Castillo Cano, Daniel Massó-Vallés, Laia Foradada Felip, Sergio López-Estévez, Erika Serrano Del Pozo, Hugo Thabussot, Laura Soucek iD

Cancers · 29.01.2023 · 15 (3) · 826

DOI: 10.3390/cancers15030826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 29.01.2023. Verfasst von Marie-Eve Beaulieu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Peptomyc S.L., Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Council, Ministerio de Ciencia e Innovacion, European Union’s Horizon 2020 research and innovation programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum.

Schlagwörter

Stichwörter der Autor:innen

LC-PRMMYCOmomycmass spectrometryprotein therapeutics

Autor:innen und Institutionen

  • Peptomyc S.L., Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Preclinical & Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
  • Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.

ORCID-Profile: Laura Soucek

Förderung

  • European Council
  • Ministerio de Ciencia e Innovacion
  • European Union’s Horizon 2020 research and innovation programme

Zitieren

APA

Beaulieu, M. E., Martínez-Martín, S., Kaur, J., Castillo Cano, V., Massó-Vallés, D., Foradada Felip, L., López-Estévez, S., Serrano Del Pozo, E., Thabussot, H., & Soucek, L. (2023). Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue. Cancers, 15(3), 826. https://doi.org/10.3390/cancers15030826

Vancouver

Beaulieu ME, Martínez-Martín S, Kaur J, Castillo Cano V, Massó-Vallés D, Foradada Felip L, et al. Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue. Cancers. 2023;15(3):826. doi:10.3390/cancers15030826

BibTeX
@article{Beaulieu2023,
  author = {Beaulieu, Marie-Eve and Martínez-Martín, Sandra and Kaur, Jastrinjan and Castillo Cano, Virginia and Massó-Vallés, Daniel and Foradada Felip, Laia and López-Estévez, Sergio and Serrano Del Pozo, Erika and Thabussot, Hugo and Soucek, Laura},
  title = {Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {826},
  doi = {10.3390/cancers15030826}
}
Kostenlos starten →